2024
‘Case of the Month’ from The University of Texas MD Anderson Cancer Center, Houston, Texas, USA: ependymoma of the urinary bladder
Myers A, Tan W, de Groot J, Westney O, Kamat A. ‘Case of the Month’ from The University of Texas MD Anderson Cancer Center, Houston, Texas, USA: ependymoma of the urinary bladder. BJU International 2024, 134: 45-47. PMID: 38379218, DOI: 10.1111/bju.16302.Peer-Reviewed Original ResearchInfluence of lamina propria invasion extension on T1 high‐grade non‐muscle‐invasive bladder cancer in patients undergoing BCG or radical cystectomy
Contieri R, Tan W, Grajales V, Hensley P, Martini A, Bree K, Myers A, Nogueras‐Gonzalez G, Navai N, Dinney C, Guo C, Kamat A. Influence of lamina propria invasion extension on T1 high‐grade non‐muscle‐invasive bladder cancer in patients undergoing BCG or radical cystectomy. BJU International 2024, 133: 733-741. PMID: 38374533, DOI: 10.1111/bju.16293.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerImmediate radical cystectomyCancer-specific survivalMetastasis-free survivalProgression-free survivalT1 substagingOverall survivalRadical cystectomyPathology reportsBladder cancerHigh-grade non-muscle-invasive bladder cancerPatients treated with bacillus Calmette-GuerinAssociated with poor progression-free survivalInstitutional review board-approved retrospective studyPatients treated with BCGPoor progression-free survivalLamina propriaAssociated with upstagingBCG-treated patientsCalculate overall survivalTreated with BCGKaplan-Meier methodHigh-grade patientsMultivariate Cox modelInvasive characteristicsComparison between high-flow nasal cannula and conventional oxygen therapy in COVID-19 patients: a systematic review and meta-analysis
Wang J, Peng Y, Dai B, Hou H, Zhao H, Wang W, Tan W. Comparison between high-flow nasal cannula and conventional oxygen therapy in COVID-19 patients: a systematic review and meta-analysis. Therapeutic Advances In Respiratory Disease 2024, 18: 17534666231225323. PMID: 38230522, PMCID: PMC10798115, DOI: 10.1177/17534666231225323.Peer-Reviewed Original ResearchConceptsAcute hypoxemic respiratory failureHigh-flow nasal cannulaConventional oxygen therapyCOVID-19-related acute hypoxemic respiratory failureIntensive care unitHospital length of stayInvasive mechanical ventilationLength of stayIntensive care unit settingCOVID-19 patientsIntubation rateNasal cannulaMechanical ventilationOxygen therapyRatio of arterial oxygen partial pressure to fractional inspired oxygenHospital lengthArterial oxygen partial pressure to fractional inspired oxygenEfficacy of high-flow nasal cannulaIntensive care unit length of stayControlled trialsSystematic reviewRespiratory support strategiesIntensive care unit lengthHypoxemic respiratory failureMortality rate
2023
Symptomatic benefits of testosterone treatment in patient subgroups: a systematic review, individual participant data meta-analysis, and aggregate data meta-analysis
Hudson J, Cruickshank M, Quinton R, Aucott L, Wu F, Grossmann M, Bhasin S, Snyder P, Ellenberg S, Travison T, Brock G, Gianatti E, van der Schouw Y, Emmelot-Vonk M, Giltay E, Hackett G, Ramachandran S, Svartberg J, Hildreth K, Antonic K, Tenover J, Tan H, Ho Chee Kong C, Tan W, Marks L, Ross R, Schwartz R, Manson P, Roberts S, Skovsager Andersen M, Velling Magnussen L, Aceves-Martins M, Gillies K, Hernández R, Oliver N, Dhillo W, Bhattacharya S, Brazzelli M, Jayasena C. Symptomatic benefits of testosterone treatment in patient subgroups: a systematic review, individual participant data meta-analysis, and aggregate data meta-analysis. The Lancet Healthy Longevity 2023, 4: e561-e572. PMID: 37804846, DOI: 10.1016/s2666-7568(23)00169-1.Peer-Reviewed Original ResearchConceptsBenefits of testosterone treatmentData meta-analysisParticipant data meta-analysisSerum total testosteroneBaseline serum total testosteroneMild erectile dysfunctionTestosterone treatmentParticipant dataMeta-analysisPatient ageIIEF-15Sexual functionTotal testosteroneErectile dysfunctionSymptomatic benefitLow testosteroneSerum total testosterone concentrationsAging Male Symptoms ScoreSystematic reviewBaseline serum testosteroneHealth Technology Assessment programmeOlder menIIEF-15 scoreTestosterone replacement therapyMinimal clinically important differenceOncological Outcomes for Patients with European Association of Urology Very High-risk Non–muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy
Contieri R, Hensley P, Tan W, Grajales V, Bree K, Nogueras-Gonzalez G, Lee B, Navai N, Dinney C, Kamat A. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non–muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy. European Urology Oncology 2023, 6: 590-596. PMID: 37558542, DOI: 10.1016/j.euo.2023.07.012.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerCancer-specific mortalityBacillus Calmette-GuerinHigh-grade recurrenceHigh-risk non-muscle-invasive bladder cancerOverall survivalBladder cancerEuropean Urological AssociationOncological outcomesNo significant differenceEarly RCPatients treated with bacillus Calmette-GuerinTreated with bacillus Calmette-GuerinNon-muscle invasive bladder cancerIntravesical BCGContemporary cohort of patientsCancer-specific mortality ratesProgression rateBacillus Calmette-Guerin groupEarly radical cystectomyMedian follow-upInvasive bladder cancerSignificant differenceCohort of patientsEarly surgical removalImpact of age >70 years on oncological outcomes in patients with non‐muscle‐invasive bladder cancer treated with Bacillus Calmette–Guérin
Contieri R, Grajales V, Tan W, Martini A, Sood A, Hensley P, Bree K, Lobo N, Nogueras‐Gonzalez G, Guo C, Navai N, Dinney C, Kamat A. Impact of age >70 years on oncological outcomes in patients with non‐muscle‐invasive bladder cancer treated with Bacillus Calmette–Guérin. BJU International 2023, 133: 63-70. PMID: 37442564, PMCID: PMC10787034, DOI: 10.1111/bju.16127.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerBacillus Calmette-GuerinCancer-specific mortalityCompeting-risk regression analysisCohort of patientsOncological outcomesFood and Drug AdministrationHG recurrenceAssociated with adverse oncologic outcomesHigh-gradeImpact of ageInstitutional review board-approved retrospective studyBacillus Calmette-Guerin instillationsIntravesical BCGCumulative incidence of progressionAdverse oncologic outcomesIncidence of progressionAssociation of advanced ageUnited States Food and Drug AdministrationStates Food and Drug AdministrationCumulative incidence methodPredictors of progressionStudy's primary outcomeBCG instillationRegression analysisSequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non–muscle-invasive Bladder Cancer
Tan W, McElree I, Davaro F, Steinberg R, Bree K, Navai N, Dinney C, O'Donnell M, Li R, Kamat A, Packiam V. Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non–muscle-invasive Bladder Cancer. European Urology Oncology 2023, 6: 531-534. PMID: 37468392, DOI: 10.1016/j.euo.2023.06.011.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerBacillus Calmette-GuerinIntermediate-risk non-muscle-invasive bladder cancerInternational Bladder Cancer GroupBladder cancerIntermediate-riskMulti-institutional retrospective reviewBlue light cystoscopyCombination of docetaxelEvaluate oncological outcomesHigh-grade diseaseMedian follow-upCancer-specific mortalityTreatment groupsCancer control outcomesBladder cancer groupSequential gemcitabineChemotherapy combinationsOncological outcomesIntravesical gemcitabinePostoperative chemotherapyAdjuvant treatmentRetrospective reviewRecurrence rateCancer groupClinical trial design for non-muscle-invasive bladder cancer
Tan W, Hall E, Kamat A, Kelly J. Clinical trial design for non-muscle-invasive bladder cancer. Nature Reviews Urology 2023, 20: 575-576. PMID: 37328547, DOI: 10.1038/s41585-023-00789-0.Peer-Reviewed Original ResearchBacillus Calmette–Guérin (BCG) unresponsive non‐muscle‐invasive bladder cancer: are the subgroups equal?
Tan W, Grajales V, Bree K, Li R, Nogueras‐Gonzalez G, Navai N, Dinney C, Kamat A. Bacillus Calmette–Guérin (BCG) unresponsive non‐muscle‐invasive bladder cancer: are the subgroups equal? BJU International 2023, 132: 384-386. PMID: 37246493, DOI: 10.1111/bju.16087.Peer-Reviewed Original ResearchReply to Arnulf Stenzl, Morgan Rouprêt, J. Alfred Witjes, Paolo Gontero. High-quality Transurethral Resection of Bladder Tumour Needs Additional Forms of Tumour Delineation. Eur Urol 2023;83:193–4
Heer R, Tan W, Gravestock P, Vadiveloo T, Lewis R, Penegar S, Vale L, MacLennan G, Hall E, Team P. Reply to Arnulf Stenzl, Morgan Rouprêt, J. Alfred Witjes, Paolo Gontero. High-quality Transurethral Resection of Bladder Tumour Needs Additional Forms of Tumour Delineation. Eur Urol 2023;83:193–4. European Urology 2023, 85: 309-312. PMID: 37330372, DOI: 10.1016/j.eururo.2023.05.040.Peer-Reviewed Original ResearchRobot-assisted Radical Cystectomy Versus Open Radical Cystectomy: A Systematic Review and Meta-analysis of Perioperative, Oncological, and Quality of Life Outcomes Using Randomized Controlled Trials
Khetrapal P, Wong J, Tan W, Rupasinghe T, Tan W, Williams S, Boorjian S, Wijburg C, Parekh D, Wiklund P, Vasdev N, Khan M, Guru K, Catto J, Kelly J. Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy: A Systematic Review and Meta-analysis of Perioperative, Oncological, and Quality of Life Outcomes Using Randomized Controlled Trials. European Urology 2023, 84: 393-405. PMID: 37169638, DOI: 10.1016/j.eururo.2023.04.004.Peer-Reviewed Original ResearchConceptsRobot-assisted radical cystectomyOpen radical cystectomyRadical cystectomyBlood lossThromboembolic eventsAssociated with better physical functionBladder cancerPositive surgical margin rateAssociated with more blood lossRisk of thromboembolic eventsHealth-related QoLQuality of life outcomesProgression-free survivalSurgical margin rateLymph node yieldRobot-assisted approachShorter operative timeShorter hospital lengthQuality of lifeRandomized controlled trialsSystematic literature searchPhysical functionWeb of ScienceNode yieldOverall survivalEvolving systemic management of urothelial cancers
Tan W, Tan M, Alhalabi O, Campbell M, Kamat A, Gao J. Evolving systemic management of urothelial cancers. Current Opinion In Oncology 2023, 35: 186-199. PMID: 36966497, DOI: 10.1097/cco.0000000000000942.Peer-Reviewed Original ResearchConceptsPlatinum-based chemotherapyInvasive bladder cancerBladder cancerAntibody-drug conjugatesFibroblast growth factor receptorCheckpoint inhibitorsUrothelial carcinomaProgrammed cell death-ligand 1 inhibitorsLocalized muscle invasive bladder cancerImprove bladder cancer outcomesNonmuscle invasive bladder cancerTraditional platinum-based chemotherapyProgrammed cell death 1Management of urothelial carcinomaMuscle invasive bladder cancerImmune checkpoint inhibitorsCell death 1Third-line optionBladder cancer outcomesResponse to therapyGrowth factor receptorFood and Drug AdministrationDeath-1Second-lineSystemic treatmentThe effects of flow settings during high-flow nasal cannula support for adult subjects: a systematic review
Li J, Albuainain F, Tan W, Scott J, Roca O, Mauri T. The effects of flow settings during high-flow nasal cannula support for adult subjects: a systematic review. Critical Care 2023, 27: 78. PMID: 36855198, PMCID: PMC9974062, DOI: 10.1186/s13054-023-04361-5.Peer-Reviewed Original ResearchConceptsHigh-flow nasal cannulaHigh-flow nasal cannula treatmentIn vivo studiesPatient's peak inspiratory flowHigh-flow nasal cannula supportFraction of inspired oxygenPositive end-expiratory pressurePeak inspiratory flowSystematic reviewEnd-expiratory pressureDead space washoutNon-dependent lung regionsIn vitro studiesRisk of biasROX indexNasal cannulaClinical findingsImprove oxygenationPediatric populationPatient discomfortAlveolar overdistentionInspiratory flowWeb of SciencePatient comfortPatients
2022
Reply to Suman Sahoo, Abhishek Pandy, Swarnendu Mandal, Manoj Kumar Das, and Prasant Nayak’s Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003
Tan W, Mustard C, Kelly J, team H. Reply to Suman Sahoo, Abhishek Pandy, Swarnendu Mandal, Manoj Kumar Das, and Prasant Nayak’s Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003. European Urology 2022, 83: e48-e49. PMID: 36456403, DOI: 10.1016/j.eururo.2022.11.006.Peer-Reviewed Original ResearchReply to Fabio Campodonico, Francesca Mattioli, and Carlo Introini’s Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003
Tan W, Kelly J, team H. Reply to Fabio Campodonico, Francesca Mattioli, and Carlo Introini’s Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003. European Urology 2022, 83: e29-e30. PMID: 36272948, DOI: 10.1016/j.eururo.2022.10.009.Peer-Reviewed Original ResearchComparison of Long-term Outcomes for Young and Healthy Patients with cT1a and cT3a Renal Cell Carcinoma Treated with Partial Nephrectomy
Tan W, Koelker M, Campain N, Cole A, Labban M, Mossanen M, Barod R, Kibel A, Chang S, Bex A, Trinh Q. Comparison of Long-term Outcomes for Young and Healthy Patients with cT1a and cT3a Renal Cell Carcinoma Treated with Partial Nephrectomy. European Urology Focus 2022, 9: 333-335. PMID: 36241545, DOI: 10.1016/j.euf.2022.09.018.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaLocally advanced kidney cancerPositive surgical marginsPartial nephrectomyAdvanced kidney cancerSurgical marginsKidney cancerRate of surgical marginComparison of long-term outcomesNational Cancer DatabaseMedian follow-upPatients aged <Cox proportional-hazards modelLong-term outcomesPresence of tumorCharlson Comorbidity IndexChronic kidney diseaseProportional-hazards modelCT1a tumorsCT1b groupHigher ACMNephron preservationCT stagingSolitary kidneyCell carcinomaRobotic surgery: getting the evidence right
Tan W, Ta A, Kelly J. Robotic surgery: getting the evidence right. The Medical Journal Of Australia 2022, 217: 391-393. PMID: 36183333, PMCID: PMC9828009, DOI: 10.5694/mja2.51726.Peer-Reviewed Original ResearchAdjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial
Tan W, Prendergast A, Ackerman C, Yogeswaran Y, Cresswell J, Mariappan P, Phull J, Hunter-Campbell P, Lazarowicz H, Mishra V, Rane A, Davies M, Warburton H, Cooke P, Mostafid H, Wilby D, Mills R, Issa R, Kelly J. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. European Urology 2022, 83: 497-504. PMID: 35999119, DOI: 10.1016/j.eururo.2022.08.003.Peer-Reviewed Original ResearchConceptsIntermediate-risk non-muscle-invasive bladder cancerNon-muscle-invasive bladder cancerDisease-free survivalAdverse eventsBladder cancerMitomycin CChemotherapy instillationOpen-labelControl armAdjuvant intravesical chemotherapyProgression-free survivalPhase 2 randomised controlled trialIntention-to-treat analysisLow gradePer-protocol analysisChemohyperthermia groupIntravesical chemotherapyUrinary cytologyHeated chemotherapyOverall survivalWeekly instillationsTumor resectionPrimary endpointRandomised controlled trialsChemohyperthermiaIntermediate-risk Non–muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group
Tan W, Steinberg G, Witjes J, Li R, Shariat S, Roupret M, Babjuk M, Bivalacqua T, Psutka S, Williams S, Cookson M, Palou J, Kamat A. Intermediate-risk Non–muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group. European Urology Oncology 2022, 5: 505-516. PMID: 35718695, DOI: 10.1016/j.euo.2022.05.005.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerInternational Bladder Cancer GroupBladder cancer groupManagement of patientsIntermediate-riskIntravesical treatmentCancer groupRisk factorsClinical trialsIntravesical chemotherapyMultifocal tumorsEarly recurrenceTumor sizeBladder cancerFrequent recurrenceHeterogeneous diseaseGrading systemCarcinoma in situStage of tumorPostoperative intravesical chemotherapyRandomized clinical trialsMaintenance BCGComparison of outcomesRecurrent diseaseClinical practice guidanceA gender-related dichotomy in bladder cancer.
Cimadamore A, Teoh J, DI Trapani E, Krajewski W, Tan W, Mori K, Del Giudice F, Carrion D, Moschini M. A gender-related dichotomy in bladder cancer. Minerva Urologica E Nefrologica 2022, 74: 376-378. PMID: 35607787, DOI: 10.23736/s2724-6051.22.04954-0.Peer-Reviewed Original Research